R5XA Stock Chart & Stats
€0.89
€0.02(3.95%)
At close: 4:00 PM EST
€0.89
€0.02(3.95%)
Day’s Range― - ―
52-Week Range€0.30 - €1.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€58.80M
Enterprise Value€37.54
Total Cash (Recent Filing)€21.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Aug 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.73Price Target Upside206.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityA zero debt position and positive equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, supports funding of trial operations, and gives management optionality to pursue non-dilutive partnerships or structured financings during the clinical development window.
Advanced Enrollment And Clear PMA PathwayClear enrollment progress and an articulated PMA timeline materially de-risk the regulatory path relative to earlier-stage peers. Sustained site engagement and a target regulatory submission year create a foreseeable milestone cadence that supports partnership discussions, resource planning, and potential revenue realization if approval succeeds.
Short Endpoints And Dosing Simplicity Enable Rapid ReadoutsA 24/72-hour endpoint and consistent first-dose targeting shorten trial risk and compress time to pivotal data, making outcomes resolvable faster than many clinical programs. Operational simplicity and predictable pharmacodynamics improve trial efficiency and reduce prolonged enrollment exposure, aiding timely regulatory and commercial planning.
Bears Say
Minimal Revenue And Persistent Cash BurnRevenue is effectively nonexistent while operating losses and negative cash flow persist, creating structural funding needs until commercialization. Continued burn without durable revenue increases the probability of dilutive financings or onerous funding terms, constraining long-term investment and strategic flexibility absent clinical success.
Dependence On Conditional Financing Tranches (~$16M)Relying on milestone‑contingent tranches concentrates funding risk on execution and timing. If enrollment or data timing slips, expected proceeds may be delayed or lost, forcing hurried or dilutive alternatives. This makes multi‑quarter planning and commercialization investments contingent on single trial outcomes.
Enrollment Concentration And Timing Variability RiskHigh enrollment concentration at a few sites and acknowledged 'ebbs and flows' heighten single-site or regional disruption risk. Late site additions are limited, so any slowdown at key centers can materially delay LPO and top-line timing, affecting regulatory filing schedules and linked financing or partnership milestones.
Talphera News
R5XA FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was €0.30 and its highest was €1.24 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is €58.80M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 26 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -€0.035 earnings per share for the quarter, beating the consensus estimate of -€0.059 by €0.024.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.05.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -€0.035 in its last earnings report, beating expectations of -€0.059. Following the earnings report the stock price went up 5.594%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in DE:R5XA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
R5XA Stock 12 Month Forecast
Average Price Target
€2.73
▲(206.92% Upside)